Key Highlights
• Continued dominance of Class II–III devices
• Mixed structure of global and domestic companies
• Concentration in specific device categories
• Ongoing importance of clinical evidence
• Increasing importance of PMS and real-world data
The April 2026 approval data shows that the Korean medical device market continues to be driven primarily by Class II and III devices. This indicates a strong focus on moderate- to high-risk products, where clinical evidence and regulatory scrutiny are more significant compared to low-risk devices.
From a company perspective, a mixed structure of global and domestic players remains evident. Global companies tend to focus on product lifecycle expansion or indication extension strategies, while domestic companies are more active in introducing new technology-driven products. This suggests that Korea functions not only as a commercial market but also as a validation ground for new medical technologies.
Looking at device categories, approvals are increasingly concentrated in specific areas such as imaging, digital health, and therapeutic devices. This reflects both rising competition and focused market opportunities within these segments.
Clinical evidence continues to play a critical role in the approval process. While some devices may qualify for approval through clinical evaluation pathways, higher-risk devices still require robust clinical trial data. This reinforces the importance of clinical execution capabilities in Korea.
In addition, the importance of post-market surveillance (PMS) and real-world data is increasing. Data generated after approval is becoming a key component of regulatory and market strategies, particularly for global submissions such as FDA and CE.